2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the provided data, presented in a structured format.

**1) Return Rate Comparison (HIMS vs. S&P 500)**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers personalized healthcare services, including online prescriptions and over-the-counter products.

*   **Cumulative Returns:**
    *   HIMS: 113.31%
    *   VOO (S&P 500): 76.17%

*   **Divergence:**
    *   Current Divergence: 44.3
    *   Relative Divergence: 32.0
    *   Min/Max Range: -86.1 to 321.5

*   **Analysis:** HIMS has significantly outperformed the S&P 500 with a cumulative return of 113.31% compared to the S&P 500's 76.17%. The current divergence of 44.3 indicates that HIMS is performing above the S&P 500. However, the relative divergence of 32.0 suggests that its outperformance, while significant, is not at its highest level historically.

*   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0  | 1.5   |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0 | 1.5   |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1 | 2.0   |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0 | 5.5   |
| 2023-2025  | 118.0% | 80.8% | 51.0%  | 0.1  | 7.5   |

    *   **CAGR:** The Compound Annual Growth Rate (CAGR) shows highly volatile performance. The company experienced significant losses in earlier periods but has seen impressive growth in the most recent periods (2022-2024 and 2023-2025).
    *   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant risk and volatility.
    *   **Alpha:** Alpha represents the excess return compared to the market. The negative alpha values in earlier periods reflect underperformance, while the high positive alpha in 2022-2024 and 2023-2025 indicate significant outperformance.
    *   **Beta:** Beta measures the stock's volatility relative to the market. Beta values close to zero or slightly negative suggest that HIMS's price movements are not strongly correlated with the overall market.
    *   **Cap(B):** Market capitalization has increased substantially over time, indicating growth in the company's value.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 33.04
*   **Last Market Data:**
    *   Price: 33.04
    *   Previous Close: 34.1
    *   Change: -3.11 (-3.11 represents the change in price from the previous closing price. This indicates that the stock price decreased by $3.11 in the most recent trading session.)
*   **Moving Averages:**
    *   5-day SMA: 34.18
    *   20-day SMA: 36.42
    *   60-day SMA: 42.35

*   **Analysis:** The stock price is currently below all three moving averages, suggesting a short-term downward trend. The price decreasing -3.11 indicates a significant recent pullback.

**3) Indicators Analysis**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 14.61 (Oversold)
*   **PPO:** -0.30 (Bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.7 (Negative - Short-term Decline)
*   **Expected Return:** 37.2% (Expected excess return compared to S&P 500 if invested long-term)

*   **Analysis:**
    *   The MRI suggests that investment is recommended (high level), which contradicts the recent indicators that show the opposite,
    *   The RSI indicates that the stock is oversold, potentially signaling a buying opportunity.
    *   PPO is negative, indicating a bearish trend.
    *   The Hybrid Signal recommends a buy strategy.
    *   The negative change in relative divergence suggests a short-term decline.
    *   The expected return is high, suggesting confidence in the long-term potential.

**4) Recent News & Significant Events**

*   **Key Headlines:**
    *   HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
    *   Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar
    *   Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
    *   Hims & Hers Health Stock (HIMS) Opinions on Canadian Market Expansion
    *   Why HIMS Stock Is Up 36% In 2025
    *   Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?

*   **Analysis:** The news is mixed. There's positive news about AI expansion, a share repurchase program (positive for stock price), and Canadian market expansion plans. However, there are concerns about the stock sliding and a plunge in price over the past three months. The contrasting headlines create uncertainty.

**4-2) Analyst Opinions**

*   **Consensus:** No key indication provided
*   **Mean Rating:** N/A
*   **Opinions:** 12 analysts
*   **Target Price:** Avg: 44.67 / High: 85.00 / Low: 25.00
*   **Recent Rating Changes:** None provided

*   **Analysis:** The average target price of $44.67 suggests analysts believe the stock has upside potential from its current price of $33.04. However, the wide range between the high and low targets indicates significant uncertainty among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

*   **Analysis:** Revenue has been generally increasing over the recent quarters. EPS fluctuates, which can be considered a red flag and need to be further analyzed.

**6) Financial Information (Revenue, Profitability, Capital)**

*   **Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.60B    | 73.80%        |
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |

*   **Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $0.58B    | 2.72%  |
| 2025-06-30   | $0.56B    | 7.55%  |
| 2025-03-31   | $0.55B    | 9.01%  |
| 2024-12-31   | $0.48B    | 5.46%  |
| 2024-09-30   | $0.44B    | 17.18% |

*   **Analysis:** Revenue is growing consistently, and profit margins remain high, indicating strong business performance.  However, ROE has been declining, which is a concern.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) presents a mixed picture.

*   **Positives:**
    *   Significant outperformance relative to the S&P 500 over the past few years.
    *   Strong revenue growth and high profit margins.
    *   Potential for long-term growth, indicated by the high expected return (37.2%).
    *   Expansion into new areas (AI, Canada).
    *   Share repurchase program (positive for stock price).
    *   MRI suggesting High Investment Recommended.

*   **Negatives:**
    *   High historical volatility (high MDD).
    *   Recent stock price pullback and short-term downward trend (below SMAs, negative PPO, negative divergence change).
    *   Conflicting news headlines (growth vs. price decline).
    *   Declining ROE.
    *   RSI suggests "oversold" status, usually it's a good time to buy, but consider the recent high MDD indicator.

*   **Overall:**

HIMS appears to be a high-growth, high-risk stock. While it has demonstrated strong performance in the past and has promising future potential, it is also subject to significant volatility and faces some challenges.

**Investment Recommendation:**

Due to the conflicting indicators and mixed news, it is difficult to give a definitive recommendation without further research. However, based on the provided data:

*   **Aggressive Investors:** Might consider a small buy position, recognizing the high risk and potential reward.  The RSI suggests it might be a good entry point, but do further due diligence.
*   **Conservative Investors:** Should likely avoid HIMS at this time, given the high volatility and uncertainty.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.